echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Biocytogen's self-developed bispecific antibody was approved by the FDA to enter clinical trials

    Biocytogen's self-developed bispecific antibody was approved by the FDA to enter clinical trials

    • Last Update: 2022-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Biocytogen (Beijing) Pharmaceutical Technology Co.
    , Ltd.
    ("Biocytogen", stock code 02315.
    HK) announced that its IND application for its self-developed bispecific antibody YH008 (PD-1 x CD40) has been approved
    by the US FDA.
    The IND application was completed
    by Yuwa Pharmaceutical, a wholly-owned subsidiary of Biocytogen.

    The approved clinical trial, an open-label, Phase I dose-escalation study (protocol number: YH008101), will evaluate the safety, tolerability, and pharmacokinetics of YH008 monotherapy in patients with PD-(L)1-resistant advanced solid tumors and hematological tumors; At the same time, the effectiveness
    of the drug will be preliminarily assessed.

    YH008 is a bispecific antibody with both antagonistic and agonist activity of PD-1 x CD40, and its target combination is the first in the world
    In vitro and in vivo experimental results show that the activation of the CD40 pathway by YH008 must depend on the cross-linking effect
    of PD-1.
    Therefore, YH008 can conditionally activate the CD40 signaling pathway in the tumor microenvironment rich in tumor-specific T cells, avoiding systemic non-specific activation
    In addition, YH008 adopts the IgG1 subtype of ineffective response function, which avoids non-specific activation
    mediated by Fc receptors.
    In the allotransplant model, YH008 showed better antitumor activity
    than maternal monoclonal antibody and combination.
    At the same time, the antitumor activity of YH008 in vivo was also significantly better than that of PD-1 monoclonal antibody and PD-L1 x CD40 dual antibody
    In vivo pharmacological studies have shown that YH008 can effectively activate tumor-infiltrating DC cells and T cells
    In addition, in vivo experiments and GLP toxicological studies have shown that YH008 has a better safety profile
    than CD40 monoclonal antibody.

    Yi Yang, Chief Scientific Officer (CSO) of Biocytogen, said: "YH008 has PD-1-dependent CD40 agonist activity and immune synergy of the two targets
    This makes YH008 almost hepatotoxic even at very high doses, while showing good efficacy with high clinical potential

    Chen Zhaorong, CEO and Chief Medical Officer of Biocytogen and Deputy General Manager of Biocytogen, said: "YH008 is an excellent combination of Biocytogen through a large number of in vivo efficacy screening, even in cold tumor models
    With the approval of YH008's IND, the company will have more diversified products into the clinic in the future to benefit patients

    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.